- Vunakizumab (SHR-1314) è un nuovo anticorpo monoclonale diretto contro l’interleuchina 17A, che ha mostrato in modo preliminare efficacia e tollerabilità negli studi di fase I.
- Vunakizumab ha mostrato un’efficacia promettente per il trattamento della psoriasi moderata-severa, con buona tollerabilità, richiedendo ulteriori studi su casistiche più ampie e studi a lungo termine.
Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials.
To evaluate the efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis.
In this 36-week, multicenter, double-blinded, phase II study (NCT03463187), 187 eligible patients with moderate-to-severe plaque psoriasis were randomized 1:1:1:1:1 to receive vunakizumab (40, 80, 160, or 240 mg) or placebo subcutaneously, every 4 weeks, until week 12 (2 more drug administrations for the vunakizumab groups on weeks 16 and 20). The primary end point was at least 75% improvement in the Psoriasis Area and Severity Index at week 12.
At week 12, there were significantly greater proportions of responders with at least 75% improvement in the Psoriasis Area and Severity Index in all vunakizumab groups compared to placebo (40, 80, 160, and 240 mg: 56.8%, 65.8%, 81.6%, and 86.5%, respectively, vs 5.4%; p <0.001 for all); the proportions of patients achieving Physician’s Global Assessment responses of 0 or 1 were also higher with vunakizumab (45.9%, 47.4%, 60.5%, and 73.0%, respectively, vs 8.1%). No unexpected adverse effects were observed.
The study was relatively short in duration and included no active control.
Vunakizumab showed promising efficacy for moderate-to-severe plaque psoriasis, with good tolerability, warranting further investigation in larger and longer-term studies.